Charity No's. 1051610 & SC039682

TRUSTEES' REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

REFERENCE AND ADMINISTRATION DETAILS OF THE CHARITY, IT'S TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 DECEMBER 2021

CHARITY REGISTRATION NUMBERS: 1051610 & SC039682

ADDRESS St James House

Eastern Road Romford

Essex RM1 3NH

TRUSTEES:

(throughout the year)

Mrs E Holland (Chair appointed November 2021)
Mrs W Diment (Vice Chair) (Elected May 2021)
Mrs Y Norton (Vice Chair)(Retired May 2021)
Mr D Hopkins (Secretary)

Mr K Weston (Treasurer appointed November 2021)

Mrs J Roberts Mrs J McComiskey Mrs J Ainsworth Mrs K Opszala Mr J Loden Ms J Cheung Mr J McCarthy

CEO:

Mr P Howard

AUDITORS:

Messrs Hillier Hopkins LLP

51 Clarendon Road

Watford Hertfordshire WD17 1HP

BANKERS:

Barclays Bank plc

Romford Business Centre

Romford

Essex RM1 1RF

CAF Bank Ltd 25 Kings Hill Avenue

Kings Hill West Malling Kent ME19 4JQ

FOR THE YEAR ENDED 31 DECEMBER 2021

The trustees present the annual report and the audited accounts of the charity for the year ended 31 December 2021. The financial statements have been prepared in accordance with the accounting policies and comply with the charity's constitution and applicable law.

THE CHARITY

LUPUS UK is the national charity for all people affected by lupus in England, Wales, Scotland and Northern Ireland. Its objectives are to:

- educate and support patients with lupus (in all its forms), families and their carers, and to
 encourage those with the disease to be involved in managing their illness.
- raise public awareness about lupus, particularly within the medical and health professions.
- fund research into lupus, its causes, consequences and treatment.
- fund Specialist Lupus Nurses within the NHS.

The original charity, British SLE Aid Group was founded in 1978 and registered as LUPUS UK from 1996 with the new Constitution approved on 14 October 1995. The Constitution has been amended periodically since then.

Vision

A world where people with lupus can lead full and active lives.

Mission

To empower people by providing information about lupus and offering support, so their voices are heard and their condition diagnosed and managed effectively.

Trustees

The trustees of the charity who served during the year ended 31 December 2021 are shown on page 1.

The maximum number of trustees permitted is twelve, of which eight are elected by the membership at the Annual General Meeting, with the remaining four being appointed by the Board. The trustees are elected/appointed by rotation and serve a period of three years, at which point they are eligible to either stand for re-election or step down.

The Board held their four formal meetings during the year, together with additional meetings to make decisions as required by the charity.

The trustees have also formed several Committees which meet to discuss priority topics in more depth and make recommendations to the Board. At present there are Committees for; Key Performance Indicators; Incorporation; Diversity, Equality & Inclusion; Ambassadors; Centre's of Excellence; Patient Involvement in Research; and Welfare.

At the Annual General Meeting held virtually on 22 May 2021, Wendy Diment was elected as Vice-Chair/Trustee, Elaine Holland was re-elected as Treasurer/Trustee and Jan Roberts was re-elected as a trustee.

Yvonne Norton stepped down as Vice-Chair/Trustee at the end her term, having served in the role since 1990. The Board awarded Yvonne with the honorary title Trustee Emeritus in recognition of her unparalleled service and dedication to the charity.

Liz Mellon also ended her term as a trustee. The Board expressed their gratitude for her commitment and efforts during her time in the role.

Following the AGM, the Board appointed two further trustees, Jolene Cheung and James McCarthy.

At the Board's meeting in November 2021, Kevin Weston resigned from the Chair/Officer role. The Board appointed Elaine Holland as the new Chair and Kevin Weston was appointed as the new Treasurer until the end of his current term in May 2022.

FOR THE YEAR ENDED 31 DECEMBER 2021

At present, all trustees either have lupus or have family members living with the disease.

Opportunities for training are circulated to the trustees to encourage best practice and the trustees each have a copy of the NCVO publication 'The Good Trustee Guide'. New trustees are encouraged to read the Charity Commission publication, 'The Essential Trustee'.

In the summer of 2021, the Board commissioned consultants from Cass Business School to conduct the charity's first governance review. The practice of governance reviews is recommended within the Charity Governance Code. Good governance enables and supports a charity's compliance with relevant legislation and regulation. It also promotes attitudes and a culture where everything works towards fulfilling the charity's vision.

Cass Business School provided a report with recommendations for developing LUPUS UK's governance arrangements. These recommendations covered a range of areas such as the charity's legal form, performance management, practice in meetings, risk management, and delegation.

LUPUS UK's trustees have welcomed the report and are investing regular and active attention in implementing the recommendations. The highest priority recommendation was that the trustees consider changing the charity's legal form by incorporating. Great efforts have been made to expedite this and present Motions for incorporation to the membership at the 2022 AGM.

Management

The daily management of LUPUS UK is under the control of the CEO see page 1, who is responsible for staff and the running of National Office, and reports to the trustees.

Key Management Remuneration

Remuneration for key management personnel is benchmarked against the voluntary sector and is set by the trustees.

OBJECTIVES, ACTIVITIES AND PERFORMANCE

Systemic Lupus Erythematosus (SLE) usually referred to as lupus, is an autoimmune disease where the immune system is dysfunctional, mistakenly identifying the body's own tissues as foreign invaders and attacking any part of it. At present, there is no known cure. The diversity and intensity of symptoms and damage to organs can make it a very difficult and potentially disabling disease to live with. Most people who have lupus require life-long medication, the side-effects of which can lead to potential problems.

Due to the complexity of the disease, lupus will typically be diagnosed by a consultant based on classification criteria. It can sometimes affect one system of the body more intensely than others. If the kidneys are affected, it is usually referred to as lupus nephritis. If the skin and hair are the dominant parts affected, it is usually referred to as cutaneous lupus (of which discoid lupus is a recognised sub-type). Other terms may be used by clinicians to define particular aspects of the disease.

Being diagnosed with lupus can be a lonely experience as the newly diagnosed are unlikely to know anyone else with the disease. The main purposes of the charity are to bring together, support and help people living with lupus, and their families, and to advance awareness and education of the public and particularly the medical and health professions in all aspects of the disease. There are a number of keyways in which the charity does this, including its telephone helpline, Group meetings in various parts of the country and information in a number of formats. LUPUS UK provides funding for medical research into the causes and consequences of lupus and improved medication and for Specialist Lupus Nurses within the NHS, a policy priority.

FOR THE YEAR ENDED 31 DECEMBER 2021

Activities

The charity's activities continued to be impacted by the COVID-19 pandemic during 2021, with social distancing and lockdown restrictions requiring the cancellation of most face-to-face meetings and events. Even when restrictions were eased, the charity remained cautious, prioritising the safety and wellbeing of its beneficiaries above all. A significant proportion of beneficiaries continued to take extra precautions and minimise contact with others, often preferring digital solutions to face-to-face meetings.

With the rollout of the COVID-19 vaccinations picking up pace at the beginning of the year, a significant amount of time was spent during 2021 providing high-quality, trustworthy information and guidance to beneficiaries. With the assistance of well-respected expert lupus clinicians, the LUPUS UK website was regularly updated, with staff and volunteers kept abreast of all new developments.

The charity's regular Lupus Information Day events were cancelled due to the pandemic and social distancing restrictions. Therefore, the charity continued its popular series of virtual patient education seminars. These live virtual events featured expert lupus clinicians presenting on topics chosen by the patient community and then answering questions. Topics included:

- · Understanding lupus blood tests
- Diet & nutrition in lupus
- Lupus & the brain
- Getting the most from your medical appointments
- Lupus & Sjögren's syndrome
- Lupus & COVID-19 Where we are now

"I've found the whole series really helpful, especially having been diagnosed relatively recently. I feel like I've learned a lot. There is so much misinformation on the Internet, it has been great to have this resource which is delivered by experts in the field."

"I have watched the recorded seminars so I could choose my time, which has been great. They have all been very informative and presented in a clear and understandable way. I very much appreciate all the time and work that has gone into such valuable resources, thank you to all involved."

LUPUS UK continued the COVID-19 Emergency Assistance Fund in 2021 to provide financial support for people with lupus who were experiencing hardship due to the pandemic and lockdowns. During 2021, the charity awarded a further 37 grants. The fund was closed in October 2021 having provided grants to 165 applicants, awarding a total of £33,993 throughout 2020 and 2021.

"Being a self-employed childminder told to shield I lost my income over night. I was financially struggling straight away and so looked into grants. I had no help from anyone other than LUPUS UK and couldn't believe the speed of the help they supplied. Very grateful and will continue my membership as a small way of saying thank you. Amazing charity, there when needed."

LUPUS UK's volunteer-led Regional Groups predominantly continued to provide virtual peer support group meetings throughout 2021. These virtual meetings were very well received by people who had been experiencing isolation or did not feel confident attending in-person meetings.

"I felt very moved emotionally by hearing about other members' experiences during an especially trying time i.e., a pandemic. Being supported by folks who know how it feels to have life changing autoimmune diseases and associated illnesses is incredibly helpful to me as I battle with a year of isolation. Thank you for your support."

Some Regional Groups re-started small face-to-face meetings for their local members who wanted to attend. It is hoped that the threat of the pandemic will ease during 2022, allowing for a big re-opening of many groups.

FOR THE YEAR ENDED 31 DECEMBER 2021

At the end of 2021, the charity recruited a full-time staff member in the brand-new role of Volunteer Coordinator. The main branches of this role initially are to provide support to our existing volunteers, assist in establishing new support groups and to recruit volunteers for a wide range of research opportunities.

Key Performance Indicators

Our online presence has continued to grow throughout the year. At the end of the year the number of followers on social media was: Facebook 36,816 (2020: 35,242), Twitter 10,382 (2020: 9,882), Instagram 8,841 (2020: 7,461) and HealthUnlocked 29,110 (2020: 27,163). There were 558,632 (2020: 769,889) unique visits to the LUPUS UK website during 2021. There were also 42,599 (2020: 48,821) downloads of our patient publications.

Traffic to the COVID-19 pages on the LUPUS UK website was very high, demonstrating the important role of the charity in providing clear, reliable, and up-to-date information and guidance:

- www.lupusuk.org.uk/coronavirus 44,391 visits
- www.lupusuk.org.uk/covid19-vaccination 105,201 visits

In addition to our online presence, paid membership is important. During 2021 we had 368 people join the charity as paying members. There is a 'hard core' of members who have supported LUPUS UK over many years and our service to them remains very important.

Funding

The COVID-19 pandemic continued to provide a very challenging climate for charities, with many conventional and popular fundraising events cancelled due to social distancing restrictions.

Our income is derived from a variety of sources, and we typically receive tremendous support from various activities and events, which are often prompted by the personal interest of a family member or friend. During the year we saw an increase in voluntary income from donations, legacies, membership income and Gift Aid compared to 2020. Charitable Activities, as outlined below, was also up thanks to an increase in organised events. Sales of Christmas cards and other items, and Investment Income make up the rest of overall income. The Trustees ensure that the charity is not reliant on any one source of income. The charity does not use the personal information of members and supporters for marketing purposes and does not use call centres for fundraising.

During the early part of the year, with another national lockdown preventing many typical fundraising events, people continued to innovate in order to support LUPUS UK. With many organised fundraising events cancelled or postponed, lots of fundraisers took on virtual challenges that can be done alone or over the internet. During Lupus Awareness Month we launched the 31-mile challenge, encouraging people to go one mile a day throughout October and collect sponsors. 77 people took on the challenge and together raised a wonderful £12,325.

In the autumn, many large organised fundraising events returned, including the London Marathon, Great North Run and Royal Parks Half Marathon.

A significant contributor to our income has been people choosing to support LUPUS UK with a Facebook Birthday fundraiser. Hundreds of supporters did this for the charity in 2021, raising an overall total of £44,723.

During 2021, World Lupus Day (10 May) and Lupus Awareness Month in October focused the attention of our members and supporters to publicise the disease and the impact it can have on lives.

FOR THE YEAR ENDED 31 DECEMBER 2021

Information

The LUPUS UK website (www.lupusuk.org.uk) is packed with information and guidance and includes the Eclipse – Light Sensitivity area for those with light sensitivity problems. LUPUS UK was accredited by the Information Standard and is currently undergoing assessment for the scheme's replacement, the Patient Information Forum (PIF) Tick Scheme. These accreditations enable the charity to display information on NHS websites and help the public to identify reliable sources of evidence-based information.

LUPUS UK keeps in regular contact with lupus specialists and lupus nurses, who may, via the LUPUS UK website, link into the section 'Information for Medical Professionals', which includes information and the procedure for grant applications. The charity is grateful for the advice and help of its Scientific and Medical Advisory Peer Review Panel for assessing grant applications and additional matters, along with the support of other medical professionals. Recognising the importance of lupus awareness within both the medical profession and the wider public, one of the charity's aims is to provide literature and information to all people with lupus via lupus and rheumatology clinics.

LUPUS UK works closely with the UK Juvenile SLE Cohort Study: a collaboration between 23 paediatric hospitals around the UK, looking into the incidence, causes and treatment of lupus in children and young people, of which over 700 are now enrolled on its various research projects. This will give further information about how they are affected by lupus, standards of care and best treatment.

LUPUS UK gives its Centres of Excellence award in recognition of the excellent care of lupus patients and productive research into the disease. Ten hospitals have so far received this recognition: Queen Elizabeth/City Hospitals, Birmingham; Manchester Royal Infirmary; Alder Hey Children's Hospital, Liverpool; University College London Hospital; the Louise Coote Lupus Unit, Guy's & St Thomas' Hospital, London; the Royal National Hospital for Rheumatic Diseases, Bath; Addenbrooke's Hospital, Cambridge; University Hospital Southampton; Great Ormond Street Hospital; and Barts Health Lupus Centre, Mile End Hospital, London.

LUPUS UK continues to be an active member of LUPUS UK EUROPE.

Risk Management

Following recommendations from the charity's governance review, LUPUS UK's Risk Map was revised and will henceforth be reviewed by the Officers each summer in addition to the usual Board review which examines the major strategic, business and operational risks that the charity faces so that any necessary steps can be taken to review and lessen these risks.

The Risk Map covers five key areas: Operational, Governance, Legal & Regulatory, Financial, and Environment & External. In each area the trustees consider the likelihood and impact of risks and consider ways to mitigate any potentially adverse effects. As examples, the charity ensures that it is not reliant on any one source of income, also all payments over the value of £5,000 require the second signature/authorisation of the Treasurer or Chair. LUPUS UK continues to review its requirements under GDPR (General Data Protection Regulation) and ensure its policy is practiced by all.

LUPUS UK has a robust reserves policy to ensure ongoing financial viability. Please see below.

Grant Making Policy

To reduce pressure on members of the Scientific & Advisory Peer Review Panel who were assisting with the pandemic response, the trustees held a single round of research grant funding. During 2021 the trustees approved Grants totaling £166,940, following recommendations of the Peer Review

FOR THE YEAR ENDED 31 DECEMBER 2021

Panel. At the end of 2021 the charity's commitment to fund Grants over the next five years stands at £1,172,312. We continue to receive more applications than we have funds available.

The charity invites applications for the funding of research projects and Specialist Lupus Nurses. Applications for research funding are reviewed against specific criteria and research objectives by the Peer Review Panel, who make their recommendations to the trustees.

As LUPUS UK does not have sufficient funding available for large-scale research projects; it will continue to support applications that focus on the following:

- smaller pilot studies, which may lead to applications to major funders for large-scale research trials.
- enabling grants for basic science support, which would enable larger projects by providing essential data for large grant applications.
- medical meetings that would facilitate improvements to the understanding of the causes, prevention and treatment of lupus and its research.

LUPUS UK is a partner of the National Institute for Health Research (NIHR) and a patient group partner of the Scottish Medicines Consortium.

The charity funds Specialist Lupus Nurses within the NHS and seeks a commitment that these posts will become permanently funded by the Hospital Trusts at the end of the five-year funding period. Ten Specialist Lupus Nurses are currently being funded or have had funding agreed.

LUPUS UK is prudently managed with research and other grants only being approved by the trustees if funds are already held. Once the commitment has been announced, the funding is placed in a special reserve. Like most other charities, LUPUS UK has been impacted by the pandemic and economic climate and the trustees have taken account of this with regard to future budgets and will ensure that the charity tailors its commitments to its resources.

FINANCIAL REVIEW OF ACCOUNTS

The state of the charity's affairs as of 31 December 2021, with comparative information for the previous year, is shown in the accompanying financial statements. The COVID-19 pandemic has been a significant factor that has continued to have an impact on the charity in meeting its financial objectives for the year.

Total funds received during the year were £859,130 against £658,995 in the previous year. Voluntary income (Donations received, Membership and Gift Aid, see note 2) was up by £148,304 on 2020, due mainly to an increase in legacy income that was £245,343 for the year and £73,882 in 2020. Donations were down by £29,216. Investment income was up by £2,894. Charitable Activities (Fundraising) was up by £53,851 on 2020 reflecting an increase in organised events. Income from Charitable Activities (Sales) was down by £4,914, due to the lower demand for Christmas cards.

Total overall expenditure was up by £21,793. Within this figure the cost of generating voluntary income was down by £10,850 as there were few face-to-face meetings of the trustees. Fundraising costs were down slightly by £1,418. Charitable Activities — Support and Administration costs were up by £34,061, due to an increase in Grants attributable for the year of £44,030, to £152,742.

The overall surplus of income over expenditure was £265,363, compared to the figure of £87,021 for 2020, before considering a change in the value of investments. The value of investments on 31 December 2021 stood at £1,264,396, which includes the reinvestment of dividends received of £19,315 during the year, along with an increase in value of £127,538 that has been accounted for.

FOR THE YEAR ENDED 31 DECEMBER 2021

The trustees anticipate that the value will rise in the coming years as the investments are of a long-term nature.

Reserves Policy

The charity's reserves on 31 December 2021 were £1,429,782 (2020: £1,036,881). LUPUS UK needs reserves to maintain its current activities and provide funding committed for longer term projects to progress them to completion, as well as enabling the trustees to meet their day-to-day responsibilities and ensure that the charity can operate as a going concern. The trustees have considered their policy in respect of the level of their reserves and aim to retain a minimum sum in the region of one year's expenditure, which will be held on deposit at the best available rate. The reserves as of 31 December 2021 meet this policy.

Investment Management

The Investment Portfolio is controlled by Rathbones Investment Management Ltd, and quarterly valuations are forwarded together with various reports. Our investments increased in value by £127,538. Dividends received for the year totaled £19,315, which were reinvested into the investment portfolio. Interest received for the year was £100.

PUBLIC BENEFIT

The charity continues to work closely with the medical profession to raise awareness of the illness to all patients. Membership of the charity is open to all who are interested in supporting its work, whether they have lupus or not. Enquiries about the disease are regularly received from the public; the charity makes information and advice available freely to everyone upon request.

The trustees confirm that they have referred to the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives in planning future activities.

To maximise its effectiveness, LUPUS UK is actively involved with umbrella organisations such as National Voices and is a founder member of RAIRDA (Rare Autoimmune Rheumatic Diseases Alliance), along with Scleroderma & Raynaud's UK, Vasculitis UK and The British Society for Rheumatology. Established to improve care for people living with these conditions with the purpose of bringing together clinical and patient organisations and other key stakeholders in order to raise the profile of rare autoimmune rheumatic diseases, influence policy and guide future research.

In 2021, RAIRDA surveyed people in Wales living with these conditions following many reports of inadequate healthcare provision. RAIRDA submitted evidence, including findings from the survey, to the Welsh Government's consultation on guidance for services for people with arthritis and long-term musculoskeletal conditions. The alliance informed the Welsh Government of a clear need to improve care for people with RAIRDs in Wales. The evidence indicates that patients in Wales, on average, have more problems with their care than those in the rest of the UK. Whilst there is some good care in Wales and some clinicians with specific expertise in RAIRDs, we believe the lack of a commissioned specialised centre in Wales is a major reason for this difference.

RAIRDA also campaigned for improved accessibility of third primary doses of COVID-19 vaccine for people who are immunosuppressed. The alliance conducted an online survey revealing that nearly one quarter (22%) in England with a rheumatic disease, whose treatment affects their immune system, were still unable to access a third primary COVID-19 vaccine dose more than two months after the JCVI issued the recommendation.

As a member of the World Lupus Federation, LUPUS UK aims to link up with other lupus organisations around the world to raise public awareness of the disease.

FOR THE YEAR ENDED 31 DECEMBER 2021

RELATED PARTIES

There were no related party transactions.

FUTURE PLANS

The trustees intend to incorporate the charity by establishing a Foundation Model Charitable Incorporated Organisation (CIO) and merging with the original charity. This will significantly reduce personal liability of the trustees if something were to go wrong. By taking this step the role of trustee should be made less onerous and could reduce deterrents to potential trustees volunteering to join the Board.

LUPUS UK plans to continue to raise lupus awareness and to advise and inform people about the

The funding of lupus research and Specialist Lupus Nurses continues to be a main priority. Funding for these is dictated by financial income and the charity will not commit to such expenditure unless the funds are already held. The charity plans to increase income in order to fund three Specialist Lupus Nurses every two years. Presently, up to one Specialist Lupus Nurse is funded each year. These areas are unlikely to change in the future but will be further assisted by the use of digital technology and social media.

VOLUNTEER INVOLVEMENT

The National Council of LUPUS UK is made up of trustees, a representative from each of the Regional Groups (which may be managed by a volunteer committee of individuals, who are mostly lupus patients) and Regional Coordinators, who are also often lupus patients. In total, including the nationwide network of telephone Contacts who offer a listening ear, around 100 people with lupus and a smaller number of supporters conduct the affairs of the charity at local and national levels across the usual range of the charity's educational, social and fundraising activities.

The charity is frequently provided with opportunities for people living with lupus to be involved in the development of research or participate in studies and trials. The opportunities are advertised to the lupus patient community regularly and volunteers enthusiastically sign-up.

The trustees would like to record their thanks to those people who commit their time and energy to the charity in a variety of ways, particularly those who assist in the running of its local Groups, especially the Group Chairs and Regional Coordinators. We welcome offers of help from those willing to work with and support the charity in this way.

The trustees recognise the commitment and dedication of our many volunteers and are very grateful to all who take on these various roles.

DONATIONS

The charity greatly appreciates the many people, companies, trusts and other organisations who have made valued donations and support of people with lupus during the year.

Kevin Weston
Treasurer/Trustee

Date 13/05/2022

Elaine Holland Chair/Trustee ESHolland

Date 13/05/2022

STATEMENT OF TRUSTEES' RESPONSIBILITIES IN RELATION TO THE FINANCIAL STATEMENTS AS AT 31 DECEMBER 2021

The Trustees are responsible for preparing the Annual Report and financial statements in accordance with applicable laws and United Kingdom Accounting Standards (United Kingdom generally accepted accounting practice).

Law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial year, which give a true and fair view of the charity's financial activities during the year and of its financial position at the end of the year. In preparing these financial statements, the trustees are required to:

select suitable accounting policies and then apply them consistently;

observe methods and principles in the Charities SORP;

make judgements and estimates that are reasonable and prudent;

state whether applicable UK accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements; and

prepared the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping accounting records which disclose with reasonable accuracy the financial position of the charity and which enable them to ascertain the financial position of the charity and which enable them to ensure that the financial statements comply with the Charities Act 2011. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Kevin Weston

Treasurer

Date

13/05/2022

Independent Auditor's Report to the Trustees of LUPUS UK for the year ended 31 December 2021

Opinion

We have audited the financial statements of Lupus UK (the 'charity') for the year ended 31 December 2021 which comprise the Statement of Financial Activity, Balance Sheet, Cash Flow and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charity's affairs as at 31 December 2021, and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice;
 and
- have been prepared in accordance with the requirements of the Charities and Trustee Investment (Scotland)
 Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the trustees annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities Accounts (Scotland) Regulations 2006 require us to report to you if, in our opinion:

- the information given in the financial statements is inconsistent in any material respect with the trustees' report; or
- · proper accounting records have not been kept; or
- · the financial statements are not in agreement with the accounting records; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement set out on page 9, the trustees are responsible for the preparation of financial statements which give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with regulations made under that Act.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The specific procedures for this engagement and the extent to which these are capable of detecting irregularities, including fraud is detailed below:

- We have assessed the nature of the industry and sector, control environment and business performance including the remuneration incentives and pressures of key management;
- The primary responsibility for the prevention and detection of fraud rests with both those charged with governance of the entity and management. We consider the results of our enquiries of management about their own identification and assessment of the risks of irregularities;
- Any matters we identified having obtained and reviewed the charity's documentation of their policies and procedures relating to:
 - identifying, evaluating and complying with laws and regulations and whether they were aware of any instances of non-compliance;
 - detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected or alleged fraud;
 - the internal controls established to mitigate risks of fraud or non-compliance with laws and regulations;
- The matters discussed among the audit engagement team regarding how and where fraud might occur
 in the financial statements and any potential indicators of fraud.

As a result of these procedures, we considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud. In common with all audits under ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override, including testing journals and evaluating whether there was evidence of bias by the trustees that represented a risk of material misstatement due to fraud.

We also obtained an understanding of the legal and regulatory frameworks that the Charity operates in, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements. We focused on laws and regulations that could give rise to a material misstatement in the financial statements, including, but not limited to, the Charities Accounts (Scotland) Regulations 2006.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Hillier Hopkins LLP Statutory Auditor

Hillier Hopkus LLP

Radius House 51 Clarendon Road Watford Hertfordshire WD17 1HP

Date: 01/06/2022

Hillier Hopkins LLP is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006.

<u>LUPUS UK</u> 14

STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 DECEMBER 2021

		UNRESTRICTED	RESTRICTED	TOTAL	2020
		FUNDS	FUNDS	FUNDS	
		£	£	£	£
Income and endowments from:					
Donations and legacies		566,900	-	566,900	418,596
Charitable activities		259,464	-	259,464	205,613
Investments	2	19,415	-	19,415	16,521
Other trading activities		13,351	-	13,351	18,265
Total		859.130	-	859,130	658,995
Expenditure on: Cost of raising funds					· ·
Costs of raising voluntary					
income	3	3.910	-	3.910	14,760
Fundraising costs.	4	137,933	-	137,933	139,351
Charitable activities	5	427,054	24,870	451,924	417,863
Total		568,897	24,870	593,767	571,974
Net income/(expenditure)		290,233	(24,870)	265,363	87,021
Other recognised gains/(losses): Gains/(losses) on investment					
assets	9	127,538	-	127,538	91,018
Net movement in funds	٠	417,771	(24,870)	392,901	178.039
Fund balances January 2021		985,034	51,847	1,036,881	858,842
Fund balances December 2021 16	5	1,402,805	26,977	1,429,782	1,036,881
	-				

BALANCE SHEET AS AT 31 DECEMBER 2021

p.		UNRESTRICTED FUNDS	RESTRICTED FUNDS	TOTAL FUNDS	2020
	Note	£	£	£	£
FIXED ASSETS	7	5,098	-	5,098	3,347
INVESTMENTS	9	1,264,396	-	1,264,396	1,117,543
		1,269,494		1,269,494	1,120,890
CURRENT ASSETS	•				
Stock	10	13,662	_	13,662	13.509
Debtors	11	96,961	-	96,961	316,570
Cash at bank and in hand Cash at bank and in hand		1,184,795	26,977	1,211,772	961,120
held by Regional Groups		42,780		42,780	37,950
	•	1,338,198	26,977	1,365,175	1,329,149
CREDITORS: AMOUNTS FA	LLING				
DUE WITHIN ONE YEAR	12	(560,043)		(560,043)	(587,227)
NET CURRENT ASSETS	•	778,155	26,977	805,132	741,922
NET ASSETS CREDITORS: AMOUNTS FALLING DUE AFTER	-	2,047,649	26,977	2,074,626	1,862,812
MORE THAN ONE YEAR	13	-644844	-	(644,844)	(825,931)
	-	1,402,805	26,977	1,429,782	1,036,881
REPRESENTED BY:					
FUND BALANCES	15	1,402,805	26,977	1,429,782	1,036,881

The notes on pages 15 to 24 form part of these financial statements.

These financial statements were approved by the Trustees on: 43./5./2022

Kevin Weston Treasurer/Trustee Mull

16

STATEMENT OF CASHFLOWS

YEAR ENDED 31 DECEMBER 2021 Cash flow from operating activities Interest paid	2021 £ 261,045	2020 £ (29,307)
Net cash flow from operating activities	261,045	(29,307)
Cash flow from investing activities Payments to acquire tangible fixed assets Payments to acquire fixed asset investments Interest received Dividends received	(5.663) (19,315) 100 19,315	(3,965) (14,649) 1,872 14,649
Net cash flow from investing activities	(5,563)	(2,093)
Cash flow from financing activities	255,482	-31400
Net increase/ -decrease in cash and cash equivalents	255,482	(31,400)
Cash and cash equivalents at start date 01/01/2021	999,070	1,030,470
Cash and cash equivalents at end date 31/12/2021	1,254,552	999,070
Cash and cash equivalents consists of:		
Cash at bank and in hand Short term deposits	1,254,552	999,070
Cash and cash equivalents at end date 31/12/2021	1,254,552	999,070

NOTES TO THE FINANCIAL STATEMENTS 31ST DECEMBER, 2021

1 ACCOUNTING POLICIES

1.01 Basis of preparation of the financial statements

The financial statements are prepared on the accruals basis and under the historical cost convention with the exception of investments, which are included at market value. The financial statements have been prepared in accordance with the Statement of Recommended Practice, Accounting Standards and Reporting by Charities SORP (FRS102) effective 1 January 2019, and applicable accounting standards and the Charities Act 2011.

LUPUS UK is a charity registered in England and Scotland. The address of the charity is detailed on page one of the accounts. The nature of the charity's operations is to help relieve persons who have lupus and to advance the education of the public and the medical profession in all aspects of the disease

The financial statements have been prepared on a going concern basis as the trustees believe that no material uncertainties exist. The trustees have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements. The budgeted income and expenditure is sufficient with the level of reserves for the charity to be able to continue as a going concern.

1.02 <u>Incoming Resources</u>

Donations & Legacies, Charitable Activities, Investments and Other Trading Activities are included in incoming resources when they are receivable, except when the donors specify that they must be used in future accounting periods or donors conditions have not been fulfilled, then the income is deferred. The income and fundraising ventures are shown gross, with the associated costs included in fundraising costs. Grants are treated as income irrespective of the source of the grant.

1.03 Resources Expended

Resources expended: Cost of generating voluntary income, Fundraising costs and Charitable activities are included in the Statement of Financial Activities on an accruals basis, inclusive of the disallowable portion of VAT.

Expenditure which is directly attributable to specific activities, has been included in these cost categories. Where costs are attributable to more than one activity, they have been apportioned across the cost categories on a basis consistent with the use of these resources.

Grants payable are charged in the year when the conditions attaching to the grant is fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

NOTES TO THE FINANCIAL STATEMENTS 31ST DECEMBER 2021 (Continued)

1.04 <u>Stock</u>

Stock is valued at the lower of cost and net realisable value.

1.05 <u>Debtors</u>

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.06 <u>Creditors</u>

Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

1.07 <u>Tangible Fixed Assets</u>

Depreciation is provided on all tangible fixed assets at rates calculated to write off each asset over its expected useful economic life as follows:

Furniture, fittings & equipment

33.3% straight line basis.

1.08 <u>Investments</u>

Investments are stated at market value at the balance sheet date. The statement of financial activities includes the net gains and losses arising on revaluations and disposals throughout the year.

1.09 Fund accounting

Generally funds are unrestricted which are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Designated funds comprise restricted funds that have been set aside by the Trustees for a particular purpose.

Restricted funds are those which are only to be used for specific purposes as laid down by the donor. Expenditure which meets the criteria is charged to the fund, together with an equitable allocation of management and support costs.

1.10 <u>Taxation</u>

The charity's surpluses are derived from, and are applied towards, the maintenance of charitable activities and as such are not subject to taxation.

1.11 Operating Leases

Rentals under operating leases are charged to the statement of financial activities on a straight line basis over the lease term.

1.12 <u>Judgements & Estimates Note</u>

Estimates and Judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

1.13 <u>Financial Instruments</u>

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at there settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest rate.

	TO THE FINANCIAL STATEMENTS 31ST DECEMBER 2021		20
(Continu	ea)	2021	2020
		£	£
2	VOLUNTARY INCOME		
	Donations	246,324	275,540
	Legacies	245,343	73,882
	Membership Income	44,373	41,670
	Gift Aid Income	30,860	27,504
		566,900	418,596
	INN/FOTMENT INCOME	£	£
	INVESTMENT INCOME Listed investment income	19,315	14,649
	Bank interest	100	1,872
	Dank interest	19,415	16,521
		2021	2020
		£	£
		- ~	~
3	COST OF VOLUNTARY INCOME	3,910	14,760
		2021	2020
•	ELINDRAIGING COCTO	2021 £	2020 £
4	FUNDRAISING COSTS	£	£
4	Cost of goods sold		
4	Cost of goods sold Fundraising costs:	£ 6,242	£ 8,168
4	Cost of goods sold Fundraising costs: Staff salaries and national insurance (note 6)(30%)	£ 6,242 66,682	£ 8,168 63,614
4	Cost of goods sold Fundraising costs: Staff salaries and national insurance (note 6)(30%) Fundraising and publicity costs	£ 6,242 66,682 52,687	£ 8,168 63,614 56,207
4	Cost of goods sold Fundraising costs: Staff salaries and national insurance (note 6)(30%)	£ 6,242 66,682	£ 8,168 63,614 56,207 11,362
	Cost of goods sold Fundraising costs: Staff salaries and national insurance (note 6)(30%) Fundraising and publicity costs	£ 6,242 66,682 52,687 12,322	£ 8,168 63,614 56,207
5	Cost of goods sold Fundraising costs: Staff salaries and national insurance (note 6)(30%) Fundraising and publicity costs Printing, stationery and postage (30%) CHARITABLE ACTIVITIES	£ 6,242 66,682 52,687 12,322	£ 8,168 63,614 56,207 11,362
	Cost of goods sold Fundraising costs: Staff salaries and national insurance (note 6)(30%) Fundraising and publicity costs Printing, stationery and postage (30%) CHARITABLE ACTIVITIES	£ 6,242 66,682 52,687 12,322 137,933	£ 8,168 63,614 56,207 11,362 139,351
5 Support	Cost of goods sold Fundraising costs: Staff salaries and national insurance (note 6)(30%) Fundraising and publicity costs Printing, stationery and postage (30%) CHARITABLE ACTIVITIES	£ 6,242 66,682 52,687 12,322 137,933	£ 8,168 63,614 56,207 11,362 139,351 2020 £ 46,408
5 Support Rent, rat Staff sal	Cost of goods sold Fundraising costs: Staff salaries and national insurance (note 6)(30%) Fundraising and publicity costs Printing, stationery and postage (30%) CHARITABLE ACTIVITIES t Costs tes, service charge and insurance aries and national insurance (note 6) (70%)	£ 6,242 66,682 52,687 12,322 137,933 2021 £	£ 8,168 63,614 56,207 11,362 139,351 2020 £
5 Support Rent, rat Staff sal Printing,	Cost of goods sold Fundraising costs: Staff salaries and national insurance (note 6)(30%) Fundraising and publicity costs Printing, stationery and postage (30%) CHARITABLE ACTIVITIES t Costs tes, service charge and insurance aries and national insurance (note 6) (70%) stationery and postage (70%	£ 6,242 66,682 52,687 12,322 137,933 2021 £ 46,490 155,592 28,752	£ 8,168 63,614 56,207 11,362 139,351 2020 £ 46,408 148,431 45,986
5 Support Rent, rat Staff sal Printing, Telepho	Cost of goods sold Fundraising costs: Staff salaries and national insurance (note 6)(30%) Fundraising and publicity costs Printing, stationery and postage (30%) CHARITABLE ACTIVITIES t Costs tes, service charge and insurance aries and national insurance (note 6) (70%) stationery and postage (70% ne	£ 6,242 66,682 52,687 12,322 137,933 2021 £ 46,490 155,592 28,752 2,608	£ 8,168 63,614 56,207 11,362 139,351 2020 £ 46,408 148,431 45,986 2,220
5 Support Rent, rat Staff sal Printing, Telepho Electricit	Cost of goods sold Fundraising costs: Staff salaries and national insurance (note 6)(30%) Fundraising and publicity costs Printing, stationery and postage (30%) CHARITABLE ACTIVITIES t Costs tes, service charge and insurance aries and national insurance (note 6) (70%) stationery and postage (70% ne ty (Light & Heat)	£ 6,242 66,682 52,687 12,322 137,933 2021 £ 46,490 155,592 28,752 2,608 2,245	£ 8,168 63,614 56,207 11,362 139,351 2020 £ 46,408 148,431 45,986 2,220 1,491
5 Support Rent, rat Staff sal Printing, Telepho Electricit National	Cost of goods sold Fundraising costs: Staff salaries and national insurance (note 6)(30%) Fundraising and publicity costs Printing, stationery and postage (30%) CHARITABLE ACTIVITIES t Costs tes, service charge and insurance aries and national insurance (note 6) (70%) stationery and postage (70% ne ty (Light & Heat) Office Overheads	£ 6,242 66,682 52,687 12,322 137,933 2021 £ 46,490 155,592 28,752 2,608 2,245 12,244	£ 8,168 63,614 56,207 11,362 139,351 2020 £ 46,408 148,431 45,986 2,220 1,491 11,546
5 Support Rent, rat Staff sal Printing, Telepho Electricit National Deprecia	Cost of goods sold Fundraising costs: Staff salaries and national insurance (note 6)(30%) Fundraising and publicity costs Printing, stationery and postage (30%) CHARITABLE ACTIVITIES t Costs tes, service charge and insurance aries and national insurance (note 6) (70%) stationery and postage (70% ne ty (Light & Heat) Office Overheads ation	£ 6,242 66,682 52,687 12,322 137,933 2021 £ 46,490 155,592 28,752 2,608 2,245 12,244 3,912	£ 8,168 63,614 56,207 11,362 139,351 2020 £ 46,408 148,431 45,986 2,220 1,491 11,546 3,089
5 Support Rent, rat Staff sal Printing, Telepho Electricit National Deprecia Professi	Cost of goods sold Fundraising costs: Staff salaries and national insurance (note 6)(30%) Fundraising and publicity costs Printing, stationery and postage (30%) CHARITABLE ACTIVITIES t Costs tes, service charge and insurance aries and national insurance (note 6) (70%) stationery and postage (70% ne ty (Light & Heat) Office Overheads ation onal fees	£ 6,242 66,682 52,687 12,322 137,933 2021 £ 46,490 155,592 28,752 2,608 2,245 12,244 3,912 390	£ 8,168 63,614 56,207 11,362 139,351 2020 £ 46,408 148,431 45,986 2,220 1,491 11,546 3,089 394
5 Support Rent, rat Staff sal Printing, Telepho Electricit National Deprecia Professi "News &	Cost of goods sold Fundraising costs: Staff salaries and national insurance (note 6)(30%) Fundraising and publicity costs Printing, stationery and postage (30%) CHARITABLE ACTIVITIES t Costs tes, service charge and insurance aries and national insurance (note 6) (70%) stationery and postage (70% ne ty (Light & Heat) Office Overheads ation onal fees a Views" magazine	£ 6,242 66,682 52,687 12,322 137,933 2021 £ 46,490 155,592 28,752 2,608 2,245 12,244 3,912 390 31,526	£ 8,168 63,614 56,207 11,362 139,351 2020 £ 46,408 148,431 45,986 2,220 1,491 11,546 3,089 394 37,179
5 Support Rent, rat Staff sal Printing, Telepho Electricit National Deprecia Professi "News & RAIRDA	Cost of goods sold Fundraising costs: Staff salaries and national insurance (note 6)(30%) Fundraising and publicity costs Printing, stationery and postage (30%) CHARITABLE ACTIVITIES t Costs tes, service charge and insurance aries and national insurance (note 6) (70%) stationery and postage (70% ne ty (Light & Heat) Office Overheads ation onal fees & Views" magazine Membership Costs	£ 6,242 66,682 52,687 12,322 137,933 2021 £ 46,490 155,592 28,752 2,608 2,245 12,244 3,912 390 31,526 9,711	£ 8,168 63,614 56,207 11,362 139,351 2020 £ 46,408 148,431 45,986 2,220 1,491 11,546 3,089 394 37,179 7,293
5 Support Rent, rat Staff sal Printing, Telepho Electricit National Deprecia Professi "News &	Cost of goods sold Fundraising costs: Staff salaries and national insurance (note 6)(30%) Fundraising and publicity costs Printing, stationery and postage (30%) CHARITABLE ACTIVITIES t Costs tes, service charge and insurance aries and national insurance (note 6) (70%) stationery and postage (70% ne ty (Light & Heat) Office Overheads ation onal fees & Views" magazine Membership Costs	£ 6,242 66,682 52,687 12,322 137,933 2021 £ 46,490 155,592 28,752 2,608 2,245 12,244 3,912 390 31,526 9,711 5,712	£ 8,168 63,614 56,207 11,362 139,351 2020 £ 46,408 148,431 45,986 2,220 1,491 11,546 3,089 394 37,179 7,293 5,114
5 Support Rent, rat Staff sal Printing, Telepho Electricit National Deprecia Professi "News & RAIRDA Audit Fe	Cost of goods sold Fundraising costs: Staff salaries and national insurance (note 6)(30%) Fundraising and publicity costs Printing, stationery and postage (30%) CHARITABLE ACTIVITIES t Costs tes, service charge and insurance faries and national insurance (note 6) (70%) stationery and postage (70% ne ty (Light & Heat) Office Overheads ation conal fees & Views" magazine Membership Costs ee	£ 6,242 66,682 52,687 12,322 137,933 2021 £ 46,490 155,592 28,752 2,608 2,245 12,244 3,912 390 31,526 9,711 5,712 299,182	£ 8,168 63,614 56,207 11,362 139,351 2020 £ 46,408 148,431 45,986 2,220 1,491 11,546 3,089 394 37,179 7,293
5 Support Rent, rat Staff sal Printing, Telepho Electricit National Deprecia Professi "News & RAIRDA Audit Fe	Cost of goods sold Fundraising costs: Staff salaries and national insurance (note 6)(30%) Fundraising and publicity costs Printing, stationery and postage (30%) CHARITABLE ACTIVITIES t Costs tes, service charge and insurance aries and national insurance (note 6) (70%) stationery and postage (70% ne ty (Light & Heat) Office Overheads ation onal fees & Views" magazine Membership Costs	£ 6,242 66,682 52,687 12,322 137,933 2021 £ 46,490 155,592 28,752 2,608 2,245 12,244 3,912 390 31,526 9,711 5,712	£ 8,168 63,614 56,207 11,362 139,351 2020 £ 46,408 148,431 45,986 2,220 1,491 11,546 3,089 394 37,179 7,293 5,114 309,151

Research and Welfare Grants

Prof C Gordon Birmingham SLICC Research Nurse Paid 2021 1 Year Commitments Dr R Al-Jayyousi Specialist Lupus Nurse Leicester 2,869 20,828 40,953 83,014 Dr Y Ahmad, Spec Lupus Nurse, North Wales 46,953 83,014 20,803 20,803 20,803 20,803 20,803 83,014 30,903 46,953 83,014 30,903 20,804 20,804 20,804 20,804 20,804 20,804 20,904				Future
Dr R Al-Jayyousi Specialist Lupus Nurse, North Wales 2,869 20,828 83,014 Dr Y Ahmad, Spec Lupus Nurse, North Wales 46,953 83,014 Dr B Rhodes Sepec Nurse QE Birmingham 51,168 40,626 Dr B Rhodes Spec Nurse QE Birmingham 51,168 40,626 Dr S Hamour Renal Lupus Nurse Royal Free Hospital 42,375 57,750 58,250 Dr A Kaul St Georges Tooting Spec Lupus Nurse 29,235 52,000 180,004 Prof D Isenberg UCL-SLICC 10,000 10,000 10,000 Dr's Walker & Price Hull Uni Transitions to Illness 1,093 10,000 Prof A Rahman UCL CVR in patients with sle 13,171 1,003 Dr's Walker & Price Hull Uni Transitions to Illness 2,994 1,000 Prof Alaman UCL CVR in patients with sle 13,171 1,003 Dr's Jury & Pineda Torra UCL Blood Fats JSLE 2,994 1,000 Dr C Ciurtin et al UCL androgen receptors JSLE 6,196 1,366 Prof Maeri UCL bacterial trans and B cell activation 5,375 5 Prof M Beresford Uni Liverpool LUK & BPSU extension 3,250 1,335 Brenste		Paid 2021	1 Year	Commitments
Dr Y Ahmad, Spec Lupus Nurse, North Wales 46,953 83,014 Dr H Harris S&E Scotland Spec Lupus Nurse 49,284 201,803 Dr B Rhodes Spec Nurse QE Birmingham 51,168 40,626 Dr E Bell & Dr C Riddell Musgrave Park Belfast 74,093 72,653 104,601 Dr S Hamour Renal Lupus Nurse Royal Free Hospital 42,375 57,750 58,250 Dr A Kaul St Georges Tooting Spec Lupus Nurse 29,235 52,000 180,004 Prof D Isenberg UCL-SLICC 10,000 10,000 10,000 Dr's Walker & Price Hull Uni Transitions to Illness 1,093 1,093 Prof D Isenberg UCL-SLICC 10,000 10,000 10,000 Dr's Jury & Pineda Torra UCL Blood Fats JSLE 2,994 1,003 Prof A Rahman UCL CVR in patients with sle 13,171 1,003 Dr's Jury & Pineda Torra UCL Blood Fats JSLE 6,196 6,196 Prof Mauri UCL bacterial trans and B cell activation 5,375 6,196 Prof Mauri UCL bacterial trans and B cell activation 5,375 7,135 Prof Mauri UCL bacterial trans and B cell activation 3,250 1,335	Prof C Gordon Birmingham SLICC Research Nurse	26,970	6,743	
Dr H Harris S&E Scotland Spec Lupus Nurse 49,284 201,803 Dr B Rhodes Spec Nurse QE Birmingham 51,168 40,626 Dr E Bell & Dr C Riddell Musgrave Park Belfast 74,093 72,653 104,601 Dr S Hamour Renal Lupus Nurse Royal Free Hospital 42,375 57,750 58,250 Dr A Kaul St Georges Tooting Spec Lupus Nurse 29,235 52,000 180,004 Prof D Isenberg UCL-SLICC 10,000 10,000 10,000 Dr's Walker & Price Hull Uni Transitions to Illness 1,093 Prof A Rahman UCL CVR in patients with sle 13,171 Dr's Jury & Pineda Torra UCL Blood Fats JSLE 2,994 Dr C Ciurtin et al UCL androgen receptors JSLE 6,196 Prof Mauri UCL bacterial trans and B cell activation 5,375 Prof M Beresford Uni Liverpool LUK & BPSU extension 20,045 JSLE Beresford Uni Liverpool 1,335 Ehrenstein, UCL 23,644 Sacre, Uni Sussex, Brighton Med School 3,250 R Gilman City Hospital, Birmingham 3,120 Dr C Ciurtin UCL Macthine learning JSLE 15,960 Giles, Cohen & Co CUL Obstetrics outcomes 18,653 <td>Dr R Al-Jayyousi Specialist Lupus Nurse Leicester</td> <td>2,869</td> <td>20,828</td> <td></td>	Dr R Al-Jayyousi Specialist Lupus Nurse Leicester	2,869	20,828	
Dr B Rhodes Spec Nurse QE Birmingham 51,168 40,626 Dr E Bell & Dr C Riddell Musgrave Park Belfast 74,093 72,653 104,601 Dr S Hamour Renal Lupus Nurse Royal Free Hospital 42,375 57,750 58,250 Dr A Kaul St Georges Tooting Spec Lupus Nurse 29,235 52,000 180,0004 Prof D Isenberg UCL-SLICC 10,000 10,000 10,000 Dr's Walker & Price Hull Uni transitions to Illness 1,093 1,093 Prof A Rahman UCL CVR in patients with sle 13,171 1 Dr's Jury & Pineda Torra UCL Blood Fats JSLE 2,994 6,196 Prof Mauri UCL bacterial trans and B cell activation 5,375 6,196 Prof Mauri UCL bacterial trans and B cell activation 5,375 6,196 JSLE Beresford Uni Liverpool LUK & BPSU extension 20,045 1,335 Ehrenstein, UCL 23,644 32,604 Sacre, Uni Sussex, Brighton Med School 3,250 3,120 R Gilman City Hospital, Birmingham 3,120 1,5960 Giles, Cohen & Co UCL Obstetrics outcomes 18,653 6,217 Reynolds&Co Uni Birmingham cell-cell interaction	Dr Y Ahmad, Spec Lupus Nurse, North Wales		46,953	83,014
Dr E Bell & Dr C Riddell Musgrave Park Belfast 74,093 72,653 104,601 Dr S Hamour Renal Lupus Nurse Royal Free Hospital 42,375 57,750 58,250 Dr A Kaul St Georges Tooting Spec Lupus Nurse 29,235 52,000 180,004 Prof D Isenberg UCL-SLICC 10,000 10,000 10,000 Dr's Walker & Price Hull Uni Transitions to Illness 1,093 1,093 Prof A Rahman UCL CVR in patients with sle 13,171 2,994 Dr C Ciurtin et all UCL androgen receptors USLE 6,196 6,196 Prof Mauri UCL bacterial trans and B cell activation 5,375 6,196 Prof Mauri UCL bacterial trans and B cell activation 5,375 7,173 Prof Mauri UCL bacterial trans and B cell activation 5,375 7,173 Prof Maler Spray Uni Liverpool 1,335 1,335 Ehrenstein, UCL 23,644 3,250 1,335 Ehrenstein, UCL 23,644 3,120 3,120 Dr C Ciurtin UCL Machine learning JSLE 15,960 3,120 Giles, Cohen & Co UCL Obstetrics outcomes 18,653 6,217 Reynolds&Co Uni Birmi	Dr H Harris S&E Scotland Spec Lupus Nurse		49,284	201,803
Dr S Hamour Renal Lupus Nurse Royal Free Hospital 42,375 57,750 58,250 Dr A Kaul St Georges Tooting Spec Lupus Nurse 29,235 52,000 180,004 Prof D Isenberg UCL-SLICC 10,000 10,000 10,000 Dr's Walker & Price Hull Uni Transitions to Illness 1,093 1,093 Prof A Rahman UCL CVR in patients with sle 1,31,171 2,994 Dr C Ciurtin et al UCL androgen receptors JSLE 6,196 6,196 Prof Mauri UCL bacterial trans and B cell activation 5,375 5,375 Prof M Beresford Uni Liverpool LUK & BPSU extension 20,045 1,335 JSLE Beresford Uni Liverpool 3,250 1,335 Ehrenstein, UCL 23,644 5,375 Sacre, Uni Sussex, Brighton Med School 3,250 3,120 R Gilman City Hospital, Birmingham 3,120 1,366 Dr C Ciurtin UCL Machine learning JSLE 15,960 18,653 6,217 Reynolds&Co Uni Birmingham cell-cell interactions 17,400 5,800 Prof D'Cruz & Co Guys & St Thomascomp Neuro 6,248 18,742 Dr N Jordan & Dr D Robbins Addenbrookes 7,17	Dr B Rhodes Spec Nurse QE Birmingham	51,168	40,626	
Dr A Kaul St Georges Tooting Spec Lupus Nurse 29,235 52,000 180,004 Prof D Isenberg UCL-SLICC 10,000 10,000 10,000 Dr's Walker & Price Hull Uni Transitions to Illness 1,093 1,093 Prof A Rahman UCL CVR in patients with sle 13,171 1 Dr's Jury & Pineda Torra UCL Blood Fats JSLE 2,994 6,196 Prof Mauri UCL bacterial trans and B cell activation 5,375 5 Prof Mauri UCL bacterial trans and B cell activation 5,375 5 Prof Mauri UCL bacterial trans and B cell activation 5,375 1,335 Prof Merricon Uni Liverpool LUK & BPSU extension 20,045 1,335 JSLE Beresford Uni Liverpool LUK & BPSU extension 3,250 1,335 Ehrenstein, UCL 23,644 Sacre, Uni Sussex, Brighton Med School 3,250 R Gilman City Hospital, Birmingham 3,120 3,120 Dr C Ciurtin UCL Machine learning JSLE 15,960 6,217 Giles, Cohen & Co UCL Obstetrics outcomes 18,653 6,217 Reynolds&Co Uni Birmingham cell-cell interactions 17,400 5,800 Prof D'Cruz & Co Guys & St Thomascomp	Dr E Bell & Dr C Riddell Musgrave Park Belfast	74,093	72,653	104,601
Prof D Isenberg UCL-SLICC 10,000 10,000 10,000 Dr's Walker & Price Hull Uni Transitions to Illness 1,093 1,093 Prof A Rahman UCL CVR in patients with sle 13,171 1,093 Dr's Jury & Pineda Torra UCL Blood Fats JSLE 2,994 1,000 Dr C Ciurtin et al UCL androgen receptors JSLE 6,196 6,196 Prof Mauri UCL bacterial trans and B cell activation 5,375 5,375 Prof M Beresford Uni Liverpool LUK & BPSU extension 20,045 1,335 Ehrenstein, UCL 23,644 5,376 1,335 Ehrenstein, UCL 3,250 1,335 1,320 R Gilman City Hospital, Birmingham 3,120 3,120 3,120 Dr C Ciurtin UCL Machine learning JSLE 15,960 1,365 6,217 Reynolds&Co Uni Birmingham cell-cell interactions 17,400 5,800 Prof D'Cruz & Co Guys & St Thomascomp Neuro 6,248 18,742 Dr N Jordan & Dr D Robbins Addenbrookes 6,914 7,172 7,172 Pros A Rahman & Dr C Wincup iron deficiency 7,172 7,172 Pros S Sutton & Co Cambs Unip sychosocial in	Dr S Hamour Renal Lupus Nurse Royal Free Hospital	42,375	57,750	58,250
Dr's Walker & Price Hull Uni Transitions to Illness 1,093 Prof A Rahman UCL CVR in patients with sle 13,171 Dr's Jury & Pineda Torra UCL Blood Fats JSLE 2,994 Dr C Ciurtin et al UCL androgen receptors JSLE 6,196 Prof Mauri UCL bacterial trans and B cell activation 5,375 Prof M Beresford Uni Liverpool LUK & BPSU extension 20,045 JSLE Beresford Uni Liverpool LUK & BPSU extension 1,335 Ehrenstein, UCL 23,644 Sacre, Uni Sussex, Brighton Med School 3,250 R Gilman City Hospital, Birmingham 3,120 Dr C Ciurtin UCL Machine learning JSLE 15,960 Giles, Cohen & Co UCL Obstetrics outcomes 18,653 6,217 Reynolds&Co Uni Birmingham cell-cell interactions 17,400 5,800 Prof D'Cruz & Co Guys & St Thomascomp Neuro 6,248 18,742 Dr N Jordan & Dr D Robbins Addenbrookes 6,914 Pros S A Rahman & Dr C Wincup iron deficiency 7,172 7,172 Pros S Sutton & Co Cambs Unip sychosocial interevention 24,995 Dr Y Yusof & Co Chapel Allerton skin investigation 25,000 M Shipa & Prof M Ehrenstein UCL plasmablast 22,885 Peer Review Panel Expenses	Dr A Kaul St Georges Tooting Spec Lupus Nurse	29,235	52,000	180,004
Prof A Rahman UCL CVR in patients with sle 13,171 Dr's Jury & Pineda Torra UCL Blood Fats JSLE 2,994 Dr C Ciurtin et al UCL androgen receptors JSLE 6,196 Prof Mauri UCL bacterial trans and B cell activation 5,375 Prof Meresford Uni Liverpool LUK & BPSU extension 20,045 JSLE Beresford Uni Liverpool 1,335 Ehrenstein, UCL 23,644 Sacre, Uni Sussex, Brighton Med School 3,250 R Gilman City Hospital, Birmingham 3,120 Dr C Ciurtin UCL Machine learning JSLE 15,960 Giles, Cohen & Co UCL Obstetrics outcomes 18,653 6,217 Reynolds&Co Uni Birmingham cell-cell interactions 17,400 5,800 Prof D'Cruz & Co Guys & St Thomascomp Neuro 6,248 18,742 Dr N Jordan & Dr D Robbins Addenbrookes 6,914 Pros A Rahman & Dr C Wincup iron deficiency 7,172 7,172 Pros S Sutton & Co Cambs Unip sychosocial interevention 24,995 Drs A Wadley & J Reynolds & Co remote monitor exercise 24,997 Dr Y Yusof & Co Chapel Allerton skin investigation 25,000 M Shipa & Prof M Ehrenstein UCL plasmablast 22,885 <td>Prof D Isenberg UCL-SLICC</td> <td>10,000</td> <td>10,000</td> <td>10,000</td>	Prof D Isenberg UCL-SLICC	10,000	10,000	10,000
Dr's Jury & Pineda Torra UCL Blood Fats JSLE 2,994 Dr C Ciurtin et al UCL androgen receptors JSLE 6,196 Prof Mauri UCL bacterial trans and B cell activation 5,375 Prof M Beresford Uni Liverpool LUK & BPSU extension 20,045 JSLE Beresford Uni Liverpool 1,335 Ehrenstein, UCL 23,644 Sacre, Uni Sussex, Brighton Med School 3,250 R Gilman City Hospital, Birmingham 3,120 Dr C Ciurtin UCL Machine learning JSLE 15,960 Giles, Cohen & Co UCL Obstetrics outcomes 18,653 6,217 Reynolds&Co Uni Birmingham cell-cell interactions 17,400 5,800 Prof D'Cruz & Co Guys & St Thomascomp Neuro 6,248 18,742 Dr N Jordan & Dr D Robbins Addenbrookes 6,914 Pros A Rahman & Dr C Wincup iron deficiency 7,172 7,172 Pros S Sutton & Co Cambs Unip sychosocial interevention 24,995 Drs A Wadley & J Reynolds & Co remote monitor exercise 24,997 Dr Y Yusof & Co Chapel Allerton skin investigation 25,000 M Shipa & Prof M Ehrenstein UCL plasmablast 22,885 Peer Review Panel Expenses 1 Lupus Nurse Network Group 167	Dr's Walker & Price Hull Uni Transitions to Illness		1,093	
Dr C Ciurtin et al UCL androgen receptors JSLE Prof Mauri UCL bacterial trans and B cell activation Frof M Beresford Uni Liverpool LUK & BPSU extension JSLE Beresford Uni Liverpool JSLE Beresford Uni Liverpool Sternenstein, UCL Sacre, Uni Sussex, Brighton Med School R Gilman City Hospital, Birmingham Dr C Ciurtin UCL Machine learning JSLE Giles, Cohen & Co UCL Obstetrics outcomes Reynolds&Co Uni Birmingham cell-cell interactions Prof D'Cruz & Co Guys & St Thomascomp Neuro Frof D'Cruz & Co Guys & St Thomascomp Neuro Fros A Rahman & Dr C Wincup iron deficiency Pros S Sutton & Co Cambs Unip sychosocial interevention Drs A Wadley & J Reynolds & Co remote monitor exercise Dr Y Yusof & Co Chapel Allerton skin investigation M Shipa & Prof M Ehrenstein UCL plasmablast Peer Review Panel Expenses Lupus Nurse Network Group Welfare Grants Opening commitments at 1st January 2021 Commitment at 31 December 2021 Dr 1,772,312	Prof A Rahman UCL CVR in patients with sle		13,171	
Prof Mauri UCL bacterial trans and B cell activation 5,375 Prof M Beresford Uni Liverpool LUK & BPSU extension 20,045 JSLE Beresford Uni Liverpool 1,335 Ehrenstein, UCL 23,644 Sacre, Uni Sussex, Brighton Med School 3,250 R Gilman City Hospital, Birmingham 3,120 Dr C Ciurtin UCL Machine learning JSLE 15,960 Giles, Cohen & Co UCL Obstetrics outcomes 18,653 6,217 Reynolds&Co Uni Birmingham cell-cell interactions 17,400 5,800 Prof D'Cruz & Co Guys & St Thomascomp Neuro 6,248 18,742 Dr N Jordan & Dr D Robbins Addenbrookes 6,914 Pros A Rahman & Dr C Wincup iron deficiency 7,172 7,172 Pros S Sutton & Co Cambs Unip sychosocial interevention 24,995 Drs A Wadley & J Reynolds & Co remote monitor exercise 24,997 Dr Y Yusof & Co Chapel Allerton skin investigation 25,000 M Shipa & Prof M Ehrenstein UCL plasmablast 25,000 M Shipa & Prof M Ehrenstein UCL plasmablast 22,885 Peer Review Panel Expenses 1,800 Lupus Nurse Network Group 167 Welfare Grants<	Dr's Jury & Pineda Torra UCL Blood Fats JSLE		2,994	
Prof M Beresford Uni Liverpool LUK & BPSU extension	Dr C Ciurtin et al UCL androgen receptors JSLE		6,196	
SLE Beresford Uni Liverpool	Prof Mauri UCL bacterial trans and B cell activation	5,375		
Ehrenstein, UCL 23,644 Sacre, Uni Sussex, Brighton Med School 3,250 R Gilman City Hospital, Birmingham 3,120 T C Ciurtin UCL Machine learning JSLE 15,960 Giles, Cohen & Co UCL Obstetrics outcomes 18,653 6,217 Reynolds&Co Uni Birmingham cell-cell interactions 17,400 5,800 Prof D'Cruz & Co Guys & St Thomascomp Neuro 6,248 18,742 Dr N Jordan & Dr D Robbins Addenbrookes 6,914 Pros A Rahman & Dr C Wincup iron deficiency 7,172 7,172 Pros S Sutton & Co Cambs Unip sychosocial interevention 24,995 Drs A Wadley & J Reynolds & Co remote monitor exercise 24,997 Dr Y Yusof & Co Chapel Allerton skin investigation 25,000 M Shipa & Prof M Ehrenstein UCL plasmablast 22,885 Peer Review Panel Expenses -	Prof M Beresford Uni Liverpool LUK & BPSU extension	20,045		
Sacre, Uni Sussex, Brighton Med School 3,250 R Gilman City Hospital, Birmingham 3,120 Dr C Ciurtin UCL Machine learning JSLE 15,960 Giles, Cohen & Co UCL Obstetrics outcomes 18,653 6,217 Reynolds&Co Uni Birmingham cell-cell interactions 17,400 5,800 Prof D'Cruz & Co Guys & St Thomascomp Neuro 6,248 18,742 Dr N Jordan & Dr D Robbins Addenbrookes 6,914 Pros A Rahman & Dr C Wincup iron deficiency 7,172 7,172 Pros S Sutton & Co Cambs Unip sychosocial interevention 24,995 Drs A Wadley & J Reynolds & Co remote monitor exercise 24,997 Dr Y Yusof & Co Chapel Allerton skin investigation 25,000 M Shipa & Prof M Ehrenstein UCL plasmablast 22,885 Peer Review Panel Expenses - Lupus Nurse Network Group 167 Welfare Grants 1,800 Welfare Grants COVID-19 6,650 355,902 527,468 644,844 Opening commitments at 1st January 2021 - 1,375,472 Commitment at 31 December 2021 1,172,312	JSLE Beresford Uni Liverpool		1,335	
R Gilman City Hospital, Birmingham Dr C Ciurtin UCL Machine learning JSLE Giles, Cohen & Co UCL Obstetrics outcomes 18,653 Reynolds&Co Uni Birmingham cell-cell interactions 17,400 Prof D'Cruz & Co Guys & St Thomascomp Neuro Prof D'Cruz & Co Guys & St Thomascomp Neuro Pros A Rahman & Dr C Wincup iron deficiency Pros S Sutton & Co Cambs Unip sychosocial interevention Prof Y Yusof & Co Chapel Allerton skin investigation M Shipa & Prof M Ehrenstein UCL plasmablast Peer Review Panel Expenses Lupus Nurse Network Group Welfare Grants Welfare Grants Opening commitments at 1st January 2021 Opening commitments at 1st January 2021 Commitment at 31 December 2021 15,960 18,653 1,800 3,120 15,960 16,217 18,653 6,217 18,653 6,217 18,653 6,217 18,653 6,217 18,653 6,217 18,653 6,217 18,653 6,217 18,653 6,217 18,653 6,217 18,653 6,217 18,653 6,217 18,712 7,172 7,	Ehrenstein, UCL	23,644		
Dr C Ciurtin UCL Machine learning JSLE Giles, Cohen & Co UCL Obstetrics outcomes Reynolds&Co Uni Birmingham cell-cell interactions Prof D'Cruz & Co Guys & St Thomascomp Neuro Prof D'Cruz & Co Guys & St Thomascomp Neuro Pros A Rahman & Dr D Robbins Addenbrookes Pros A Rahman & Dr C Wincup iron deficiency Pros S Sutton & Co Cambs Unip sychosocial interevention Drs A Wadley & J Reynolds & Co remote monitor exercise Dr Y Yusof & Co Chapel Allerton skin investigation M Shipa & Prof M Ehrenstein UCL plasmablast Peer Review Panel Expenses Lupus Nurse Network Group Welfare Grants Welfare Grants COVID-19 Opening commitments at 1st January 2021 Opening commitments at 1st January 2021 - 1,375,472 Commitment at 31 December 2021 15,960 6,217 17,400 5,800 18,653 6,217 17,400 5,800 7,172 7,	Sacre, Uni Sussex, Brighton Med School	3,250		
Giles, Cohen & Co UCL Obstetrics outcomes 18,653 6,217 Reynolds&Co Uni Birmingham cell-cell interactions 17,400 5,800 Prof D'Cruz & Co Guys & St Thomascomp Neuro 6,248 18,742 Dr N Jordan & Dr D Robbins Addenbrookes 6,914 Pros A Rahman & Dr C Wincup iron deficiency 7,172 7,172 Pros S Sutton & Co Cambs Unip sychosocial interevention 24,995 Drs A Wadley & J Reynolds & Co remote monitor exercise 24,997 Dr Y Yusof & Co Chapel Allerton skin investigation 25,000 M Shipa & Prof M Ehrenstein UCL plasmablast 22,885 Peer Review Panel Expenses - Lupus Nurse Network Group 167 Welfare Grants 1,800 Welfare Grants COVID-19 6,650 Opening commitments at 1st January 2021 - 1,375,472 Commitment at 31 December 2021 1,172,312	R Gilman City Hospital, Birmingham		3,120	
Reynolds&Co Uni Birmingham cell-cell interactions Prof D'Cruz & Co Guys & St Thomascomp Neuro Prof D'Cru & Co Guys & St Thomascomp Neuro Prof D'Cru & Co Guys & St Thomascomp Neuro Prof D'Cru & St Th	Dr C Ciurtin UCL Machine learning JSLE	15,960		
Prof D'Cruz & Co Guys & St Thomascomp Neuro 6,248 18,742 Dr N Jordan & Dr D Robbins Addenbrookes 6,914 Pros A Rahman & Dr C Wincup iron deficiency 7,172 7,172 Pros S Sutton & Co Cambs Unip sychosocial interevention 24,995 Drs A Wadley & J Reynolds & Co remote monitor exercise 24,997 Dr Y Yusof & Co Chapel Allerton skin investigation 25,000 M Shipa & Prof M Ehrenstein UCL plasmablast 22,885 Peer Review Panel Expenses - Lupus Nurse Network Group 167 Welfare Grants 1,800 Welfare Grants COVID-19 6,650 Opening commitments at 1st January 2021 - 1,375,472 Commitment at 31 December 2021 1,172,312	Giles, Cohen & Co UCL Obstetrics outcomes	18,653	6,217	
Dr N Jordan & Dr D Robbins Addenbrookes Pros A Rahman & Dr C Wincup iron deficiency Pros S Sutton & Co Cambs Unip sychosocial interevention Drs A Wadley & J Reynolds & Co remote monitor exercise Dr Y Yusof & Co Chapel Allerton skin investigation M Shipa & Prof M Ehrenstein UCL plasmablast Peer Review Panel Expenses Lupus Nurse Network Group Welfare Grants Welfare Grants COVID-19 Opening commitments at 1st January 2021 Commitment at 31 December 2021 - 1,375,472 Commitment at 31 December 2021 7,172	Reynolds&Co Uni Birmingham cell-cell interactions	17,400	5,800	
Pros A Rahman & Dr C Wincup iron deficiency 7,172 7,172 Pros S Sutton & Co Cambs Unip sychosocial interevention 24,995 Drs A Wadley & J Reynolds & Co remote monitor exercise 24,997 Dr Y Yusof & Co Chapel Allerton skin investigation 25,000 M Shipa & Prof M Ehrenstein UCL plasmablast 22,885 Peer Review Panel Expenses - Lupus Nurse Network Group 167 Welfare Grants 1,800 Welfare Grants COVID-19 6,650 355,902 527,468 644,844 Opening commitments at 1st January 2021 - 1,375,472 Commitment at 31 December 2021 1,172,312	Prof D'Cruz & Co Guys & St Thomascomp Neuro	6,248	18,742	
Pros S Sutton & Co Cambs Unip sychosocial interevention Drs A Wadley & J Reynolds & Co remote monitor exercise Dr Y Yusof & Co Chapel Allerton skin investigation M Shipa & Prof M Ehrenstein UCL plasmablast Peer Review Panel Expenses Lupus Nurse Network Group 167 Welfare Grants 1,800 Welfare Grants COVID-19 6,650 355,902 527,468 644,844 Opening commitments at 1st January 2021 - 1,375,472 Commitment at 31 December 2021 1,172,312	Dr N Jordan & Dr D Robbins Addenbrookes		6,914	
Drs A Wadley & J Reynolds & Co remote monitor exercise 24,997 Dr Y Yusof & Co Chapel Allerton skin investigation 25,000 M Shipa & Prof M Ehrenstein UCL plasmablast 22,885 Peer Review Panel Expenses - Lupus Nurse Network Group 167 Welfare Grants 1,800 Welfare Grants COVID-19 6,650 355,902 Opening commitments at 1st January 2021 - 1,375,472 Commitment at 31 December 2021 1,172,312	Pros A Rahman & Dr C Wincup iron deficiency		7,172	7,172
Drs A Wadley & J Reynolds & Co remote monitor exercise 24,997 Dr Y Yusof & Co Chapel Allerton skin investigation 25,000 M Shipa & Prof M Ehrenstein UCL plasmablast 22,885 Peer Review Panel Expenses - Lupus Nurse Network Group 167 Welfare Grants 1,800 Welfare Grants COVID-19 6,650 355,902 527,468 644,844 Opening commitments at 1st January 2021 1,375,472 Commitment at 31 December 2021 1,172,312	Pros S Sutton & Co Cambs Unip sychosocial interevention		24,995	
M Shipa & Prof M Ehrenstein UCL plasmablast Peer Review Panel Expenses Lupus Nurse Network Group Welfare Grants 1,800 Welfare Grants COVID-19 6,650 355,902 527,468 644,844 Opening commitments at 1st January 2021 - 1,375,472 Commitment at 31 December 2021 1,172,312			24,997	
Peer Review Panel Expenses - Lupus Nurse Network Group 167 Welfare Grants 1,800 Welfare Grants COVID-19 6,650	Dr Y Yusof & Co Chapel Allerton skin investigation		25,000	
Lupus Nurse Network Group 167 Welfare Grants	M Shipa & Prof M Ehrenstein UCL plasmablast		22,885	
Welfare Grants 1,800 Welfare Grants COVID-19 6,650 355,902 527,468 644,844 Opening commitments at 1st January 2021 - 1,375,472 Commitment at 31 December 2021 1,172,312	Peer Review Panel Expenses	-		
Welfare Grants COVID-19 6,650 355,902 527,468 644,844 Opening commitments at 1st January 2021 - 1,375,472 Commitment at 31 December 2021 1,172,312	Lupus Nurse Network Group	167		
Opening commitments at 1st January 2021 - 1,375,472 Commitment at 31 December 2021 1,172,312	Welfare Grants	1,800		
Opening commitments at 1st January 2021 - 1,375,472 Commitment at 31 December 2021 1,172,312	Welfare Grants COVID-19	6,650		
Commitment at 31 December 2021 1,172,312		355,902	527,468	644,844
<u></u>	Opening commitments at 1st January 2021	- 1,375,472		
TOTAL CHARGE FOR 2021 152,742	Commitment at 31 December 2021	1,172,312		
	TOTAL CHARGE FOR 2021	152,742		

6	EMPLOYEES Staff Costs:	2021 £	2020 £
	Wages and salaries	208,508	199,086
	Social security costs	13,766	12,959
		222,274	212,045
	The average number of employees,		
	by function, was:	No.	No.
	Fundraising	3.5	3.5
	Support	5.5	4.5
		9	8

The Charity considers its key management personnel comprise the trustees and Chief Executive Officer. The total employment benefits including employer pension contributions of key management personnel were £56,238 (2020: £51,060)

No employee earned over £60,000 in 2021 or in 2020. None of the Trustees received any remuneration for their services. Expenses incurred by the Trustees for travel, accommodation and subsistence totalled £2,068 (2020: £7,175) were reimbursed by the charity.

7	FIXED ASSETS	Office Furniture and Equipment £	-
	Cost	~	
	01-Jan-21	44,340	
	Disposals	- 1,575	
	Additions	5,663	
	31-Dec-21	48,428	
	Depreciation		
	01-Jan-21	40,993	
	Disposals	- 1,575	
	Charge for the year	3,912	
	31-Dec-21	43,330	
	Net Book Amount		
	31-Dec-21	5,098	
	31-Dec-20	3,347	
8	FINANCIAL INSTRUMENTS	2021 £	2020 £
	Financial instruments measured at amortised cost	1,352,565	1,315,640
	Financial liabilities measured at amortised cost	1,204,887	1,413,158

Financial assets measured at amortised cost comprise bank and cash, trade debtors, other debtors and accrued income.

Financial liabilities measured at amortised cost comprise trade creditors, other creditors, accruals and grant commitments.

Add: Additions Less: Disposal Realised/unrea	d from previous year at cost		2021 £ 1,117,543 107,543 - 42,602 127,538 - 45,626	91,018
			1,264,396	1,117,543
Disposals dur	ing year	Units	price as at 31-Dec-20	Total value 31-Dec-20
Asia Dragon T	rust PLC 20p Ord Shares	3,150	5.28	16,632
Rio Tinto PLC	10p Ord Shares	400	54.70	21,880
	cial Inc USD0.01 Cls	20	19.69	368
Clinigen Group	PLC 0.1p Ord Shares	215	6.75	1,451
				40,331
Investments he	eld as follows:		2021 £	2020 £
	d on UK Stock Exchange		386,225	349.803
Cash			22,280	67,907
UK Fixed intere	est		168,323	168,672
Overseas Equi	ities		542,682	404,568
Alternatives			144,886	126,593
			1,264,396	1,117,543

2021

£

2020

£

9

Investments are held in a managed fund administered by Rathbone Investment Management Limited.

MATERIAL INVESTMENTS

10	STOCKS	2021 £	2020 £
	Goods for resale	13,662	13,509
		2021 £	2020 £
11	DEBTORS DUE WITHIN ONE YEAR	~	£
	Debtors	7,000	
	Prepayments and accrued income	89,961	316,570
		96,961	316,570
12	CDEDITORS, AMOUNTS THE	2021	2020
14	CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR	£	£
	Trade Creditors	27,275	32,786
	Other creditors and accruals	5,300	4,900
	Research Grants (Note 5)	527,468	549,541
		560,043	587,227
13	CREDITORS: AMOUNTS FALLING DUE	0004	
	AFTER MORE THAN ONE YEAR	2021 £	2020
	Research Grants (Note 5)	2 644.844	£
	,	044 ,0 44	825,931
		2021	2020
14	The auditors romunaration and auditors are all the same and a same	£	£
• •	The auditors remuneration amounts to an audit fee of:	5,712	5,114

15 MOVEMENT IN FUNDS

Restricted Funds:	At 01/01/2021 £	Incoming Resources £		Outgoing esources £	Gains and Losses £	At 31/12/2021 £
Helen Rayner Naomi Tate Memorial Fund (LUK)	10,470 41,377		-	24,870		10,470 16,507
Total restricted funds	51,847	-	-	24,870		26,977
Unrestricted Funds: General Funds	985,034	859,130	-	568,897	127,538	1,402,805
Total Funds	1,036,881	859,130	-	593,767	127,538	1,429,782

Unrestricted funds comprise those funds which the Trustees are free to use in accordance with the charitable objects.

Purposes of restricted funds:

The Helen Rayner Memorial Fund is to be used to support training days for GPs.

The Naomi Tate Memorial Fund (LUPUS UK) is to be used for research relating to and information/publications in respect of lupus and pregnancy.

16 ANALYSIS OF NET ASSETS BY FUND AT 31 DECEMBER 2021

	Unrestricted Funds	Restricted Funds	Total Funds
Tangible fixed assets	5,098		5,098
Investments	1,264,396		1,264,396
Stock	13,662		13,662
Debtors and prepayments	96,961		96,961
Cash at bank and in hand	1,202,705	51,847	1,254,552
Creditors due within one year	- 560,043	-	560,043
Creditors due after one year	- 644,844		644,844
NET ASSETS	1,377,935	51,847	1,429,782

17 Reconciliation of net income/-expenditure to net cash flow from operating activities

	2021 £		2020 £
	392,901		178,039
-	19,315	-	14,649
-	100	-	1,872
	3,912		3,089
-	127,538	-	91,018
-	153		122
	219,609		238,323
-	208,271	-	341,341
	261,045	-	29,307
	: : :	£ 392,901 - 19,315 - 100 3,912 - 127,538 - 153 219,609 - 208,271	\$\frac{\mathbf{x}}{2}\$ 392,901 - 19,315 - - 100 - 3,912 - 127,538 - - 153 219,609 - 208,271 -

18 OPERATING LEASE COMMITMENTS

At 31 December 2021 the charity had annual commitments under non-cancellable operating leases as follows:

	2021 Land and Buildings	2020 Land and Buildings
	Ł	Ł
Expiry Date:		
Within 1 year	12,323	25,850
Due 2 - 5 years	-	12,323
Due in more than 5 years	-	-

19 Pension Contributions

The charity operates defined contributions pension schemes. The assets of the schemes are held separately from those of the charity in independently administered funds. The pension cost charge represents contributions payable by the charity to the funds and amounted to $\pounds 9,415$ (2020 - $\pounds 8,721$). At the balance sheet date, $\pounds nil$ (2020 - $\pounds nil$) is outstanding.

20 Related Parties

Other than the expenses paid to the trustees, there were no other related party transactions during the year (2020 - £nil).